Certara Inc
(NAS:CERT)
$
13.29
0.29 (2.23%)
Market Cap: 2.14 Bil
Enterprise Value: 2.22 Bil
PE Ratio: 0
PB Ratio: 2.05
GF Score: 83/100 - Q2 2024 Certara Inc Earnings Call TranscriptAug 06, 2024$15.08 (+1.14%)Earnings
- Q1 2024 Certara Inc Earnings Call TranscriptMay 07, 2024$17.66 (+0.11%)Earnings
- Q4 2023 Certara Inc Earnings Call TranscriptFeb 29, 2024$16.88 (-0.59%)Earnings
- Certara Inc at Stephens Investment Conference TranscriptNov 15, 2023
- Q3 2023 Certara Inc Earnings Call TranscriptNov 08, 2023$12.48 (-0.79%)Earnings
- Certara Inc at Robert W Baird Global Healthcare Conference TranscriptSep 13, 2023
- Certara Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Certara Inc Earnings Call TranscriptAug 09, 2023$17.92 (-2.56%)Earnings
- Certara Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Certara Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Certara Inc Earnings Call TranscriptMay 08, 2023$23.42 (+1.34%)Earnings
- Certara Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Certara Inc Earnings Call TranscriptMar 01, 2023$18.44 (+1.77%)Earnings
- Certara Inc at Stephens Investment Conference TranscriptNov 17, 2022
- Certara Inc at Jefferies London Healthcare Conference TranscriptNov 15, 2022
- Q3 2022 Certara Inc Earnings Call TranscriptNov 07, 2022$12.74 (+19.58%)Earnings
- Certara Inc at Robert W Baird Global Healthcare Conference TranscriptSep 14, 2022
- Certara Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Q2 2022 Certara Inc Earnings Call TranscriptAug 09, 2022$22.84 (-5.35%)Earnings
- Certara Inc at William Blair Growth Stock Conference TranscriptJun 09, 2022
- Certara Inc at Jefferies Healthcare Conference TranscriptJun 08, 2022
- Certara Inc at Citi Biopharma Co-Panel Day (Virtual) TranscriptMay 18, 2022
- Certara Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q1 2022 Certara Inc Earnings Call TranscriptMay 05, 2022$18.69 (-4.84%)Earnings
- Q4 2021 Certara Inc Earnings Call TranscriptMar 01, 2022$24.66 (-2.68%)Earnings
- Certara Inc Investor Day TranscriptDec 15, 2021
- Certara Inc at Piper Sandler Healthcare Conference (Virtual) TranscriptNov 22, 2021
- Q3 2021 Certara Inc Earnings Call TranscriptNov 09, 2021$41.72 (-0.81%)Earnings
- Certara Inc at Bank of America Tech Solutions for Drug Discovery Conference (Virtual) TranscriptSep 20, 2021
- Certara Inc at Robert W Baird Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Certara Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Q2 2021 Certara Inc Earnings Call TranscriptAug 05, 2021$27.99 (+0.25%)Earnings
- Certara Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 04, 2021
- Certara Inc at William Blair Growth Stock Conference (Virtual) TranscriptJun 01, 2021
- Certara Inc Annual Shareholders Meeting TranscriptMay 18, 2021
- Certara Inc at Bank of America Securities 2021 Virtual Health Care Conference (Virtual) TranscriptMay 11, 2021
- Q1 2021 Certara Inc Earnings Call TranscriptMay 06, 2021$29.38 (-6.40%)Earnings
- Q4 2020 Certara Inc Earnings Call TranscriptMar 04, 2021$30.52 (-10.00%)Earnings
Certara Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 03:40PM GMT
Release Date Price:
$20.95
(+0.19%)
Michael Leonidovich Ryskin
BofA Securities, Research Division - Director in Equity Research & Research Analyst
Thanks for joining us for this next session. My name is Mike Ryskin. I'm on the BofA life science tools and diagnostics team with the other senior analyst, Derik De Bruin. Joining us for the next session is Certara. We've got John Gallagher and Andrew Schemick joining us. The format of the chat is going to be a fireside chat, and we'll take questions from the audience as they come in. But first of all, gentlemen, thank you for joining us.
John E. Gallagher
Certara, Inc. - CFO
Thanks for having us, Mike. Glad to be here.
Michael Leonidovich Ryskin
BofA Securities, Research Division - Director in Equity Research & Research Analyst
Yes. And then maybe you guys reported 1Q very recently. I don't know if you have some opening remarks you'd like to make to kick things off.
John E. Gallagher
Certara, Inc. - CFO
Yes. I mean, look, we were pleased with the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)